bioRxiv Science⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/313957

DUSP28 is a novel biomarker responsible for aggravating malignancy via the autocrine signaling pathways in metastatic pancreatic cancer

Kim, J. H.·Lee, J.·Choi, C.
View original source ↗Export metadata ↓

Abstract

Pancreatic cancer remains one of the most dangerous cancers with a grave prognosis. We previously reported that pancreatic cancer cells can secrete dual specificity phosphatise 28 (DUSP28) to the cultured medium. However, its biological function is poorly understood. Here, we have identified the function of DUSP28 in human metastatic pancreatic cancer. Treatment with recombinant DUSP28 (rDUSP28) significantly increased the migration, invasion, and viability of metastatic pancreatic cancer cells through the activation of CREB, AKT, and ERK1/2 signaling pathways. Furthermore, rDUSP28 acted as an oncogenic reagent through the interaction with integrin 1 in metastatic pancreatic cancer cells. In addition, rDUSP28 induced pro-angiogenic effects in human umbilical vein endothelial cells (HUVECs). Administration of rDUSP28 also produced tumor growth in vivo. Notably, sDUSP28 can easily be detected by immunoassay. The results establish the rationale for sDUSP28 as a promising therapeutic target and biomarker for metastatic pancreatic cancer patients.

Source connections

Explore related subjects

cancer biologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Kim, J. H., Lee, J., Choi, C.. 2018-05-03. DUSP28 is a novel biomarker responsible for aggravating malignancy via the autocrine signaling pathways in metastatic pancreatic cancer. https://doi.org/10.1101/313957

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Adaptation of breast cancer cells to serum-free defined medium reveals changes in proliferation, adhesion, and lipid metabolism

Cancer cell metabolic dependencies are strongly influenced by nutrient availability, yet conventional culture conditions contain non-physiological nutrient concentrations and poorly defined serum components that may obscure metabolic vulnerabilities. Here, we investigated the adaptation of three breast cancer cell lines to physiologically relevant, serum-free defined medium (DM). Using a stepwise reduction in fetal bovine serum (FBS), we evaluated proliferation, adhesion, morphology, and transcriptional changes in HER2-positive SK-BR-3, triple-negative MDA-MB-231, and ER-positive/HER2-positive BT-474 cells. The three cell lines differed substantially in their ability to adapt to serum-free conditions. MDA-MB-231 cells adapted readily, maintaining proliferation and adhesion without exogenous substrate coatings. SK-BR-3 cells also achieved sustained proliferation in serum-free DM, but required a serum-derived coating to maintain adhesion. In contrast, BT-474 cells failed to sustain adhesion and proliferation following complete serum withdrawal, although they remained proliferative in medium containing 1% FBS. Adapted cells retained characteristic HER2 or vimentin expression despite changes in morphology and proliferation. RNA sequencing revealed extensive transcriptional remodeling, including reduced expression of cell-cycle-associated programs in SK-BR-3 cells and enrichment of cholesterol homeostasis gene sets in SK-BR-3 and MDA-MB-231 cells. Expression of cholesterol regulatory genes, including SREBF2, HMGCR, and LDLR, increased across all three lines. Together, these findings highlight cell-line-specific adhesion requirements and shared metabolic responses to serum withdrawal, establishing a framework for developing defined culture systems to investigate cancer metabolic dependencies through genetic screening.

cancer biology↗
bioRxiv2026

Lineage tracing in rhabdoid tumor organoids and orthotopic xenografts reveals convergent transcriptional states

Malignant rhabdoid tumors (MRTs) are aggressive pediatric malignancies driven by loss of a single SWI/SNF subunit in an otherwise near-silent genome, yet they display extensive transcriptional heterogeneity. Whether this heterogeneity reflects the outgrowth of transcriptionally distinct clones, or states adopted independently of lineage, is unknown. Here we combined lentiviral lineage barcoding with single-cell RNA sequencing in two patient-derived renal MRT organoid models, followed through long-term in vitro culture and in a novel orthotopic xenograft setting. In both modalities, tumors and cultures became progressively restricted to a small number of lineages, and the clones that expanded were transcriptionally distinct from one another. Decomposing into gene expression programs showed that some transcriptional states were used broadly across lineages while others were confined to a few, and that lineages expanding independently, in separate cultures and separate animals, converged on the same restricted states. Individual lineages generally maintained their transcriptional identity across passaging and across anatomical sites, including in metastases, which arose from clones already expanded in the matched primary tumor. Which lineages came to dominate, however, differed between animals given the same starting population. Clonal outcome is therefore variable while the transcriptional states available to a tumor are drawn from a constrained and recurring repertoire.

cancer biology↗
bioRxiv2026

The Pregnane X Receptor (PXR) contributes to phenotypic plasticity and modulates the sensitivity to targeted therapies in melanoma

The challenge in treating advanced metastatic melanoma lies in the development of therapeutic resistance and the risk of recurrence. Understanding the mechanisms underlying tumor adaptation to treatment is therefore crucial, as they can directly influence therapeutic efficacy. Tolerance to targeted therapies may be influenced by drug transport and metabolism within tumors, processes regulated by numerous genes under the transcriptional control of the nuclear receptor PXR (Pregnane X Receptor, NR1I2). We revealed, for the first time, significant and heterogeneous expression of PXR in human melanoma samples. We previously showed that PXR can be activated by BRAF inhibitors (BRAFi), but not by MEK inhibitors (MEKi), which are currently used in combination for the treatment of BRAF-V600E-mutated melanoma. Here, we investigated whether PXR expression influences melanoma cell sensitivity to MAPK pathway inhibitors. Using BRAF-mutated human melanoma cell lines, we showed that stable PXR expression sensitizes cells to combined BRAFi/MEKi treatment. Transcriptomic analysis further revealed that PXR expression is associated with the upregulation of several phenotypic markers, with MITF identified as a major regulator in untreated PXR-overexpressing cells. These findings suggest that PXR promotes a shift toward a melanocytic phenotype, which is associated with increased sensitivity to BRAFi/MEKi treatment. Characterization of the PXR-associated transcriptional signature in melanoma may therefore have translational value for identifying patients more likely to benefit from targeted therapies and support the development of PXR as a predictive biomarker of therapeutic response.

cancer biology↗